PCH
NAMS icon

Polar Capital Holdings’s NewAmsterdam Pharma NAMS Stock Holding History

Polar Capital Holdings’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-909,742
Closed -$10.2M – 299
2023
Q4 		$10.2M Buy
+909,742
New +$8.33M 0.06% 196

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Polar Capital Holdings's NAMS Position: Q2 2026 in Review

Polar Capital Holdings reduced its NewAmsterdam Pharma (NAMS) stake by 39% in Q2 2026, selling an estimated $36.5M and leaving 1,724,518 shares worth $58.4M. The position accounts for 0.14% of the portfolio, ranked #111.

Polar Capital Holdings first reported a position in NAMS in Q1 2024 and has held it in 10 quarters since. The position peaked at $97.4M in Q4 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Polar Capital Holdings held 1,724,518 shares of NewAmsterdam Pharma worth $58.4M as of Q2 2026.
  • Polar Capital Holdings sold 1,107,089 NewAmsterdam Pharma shares in Q2 2026, an estimated $36.5M.
  • NewAmsterdam Pharma made up 0.14% of Polar Capital Holdings's portfolio in Q2 2026, its #111 holding.
  • Polar Capital Holdings first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 10 quarters since.
  • Polar Capital Holdings's NewAmsterdam Pharma position peaked at $97.4M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.